CHC (4164) reported revenue of NT$346.2 million for Oct 2026, +2.5% year on year and -31.6% from the previous month. Revenue for Jan–Oct 2026 was NT$3.84 billion (+9.0% year on year).
In Oct 2026, it ranked No. 27 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$346.2 million | +2.5% | -31.6% |
| Sep 2026 | NT$506.4 million | -4.1% | +54.6% |
| Aug 2026 | NT$327.6 million | +15.4% | +0.3% |
| Jul 2026 | NT$326.5 million | +13.6% | -1.0% |
| Jun 2026 | NT$329.9 million | -38.2% | -39.3% |
| May 2026 | NT$543.5 million | +80.2% | +78.6% |
| Apr 2026 | NT$304.4 million | +21.8% | -47.3% |
| Mar 2026 | NT$577.1 million | +3.4% | +114.8% |
| Feb 2026 | NT$268.7 million | +22.8% | -14.6% |
| Jan 2026 | NT$314.7 million | +38.3% | -34.1% |
| Dec 2025 | NT$477.6 million | -1.7% | +21.2% |
| Nov 2025 | NT$394.1 million | +32.6% | +16.7% |
| Oct 2025 | NT$337.8 million | +42.2% | -36.0% |
| Sep 2025 | NT$527.9 million | +9.1% | +86.0% |
| Aug 2025 | NT$283.8 million | +10.6% | -1.2% |
| Jul 2025 | NT$287.4 million | +29.1% | -46.1% |
| Jun 2025 | NT$533.4 million | +46.5% | +76.9% |
| May 2025 | NT$301.6 million | -21.7% | +20.7% |
| Apr 2025 | NT$249.9 million | +14.0% | -55.2% |
| Mar 2025 | NT$558.3 million | +151.1% | +155.1% |
| Feb 2025 | NT$218.9 million | +30.8% | -3.8% |
| Jan 2025 | NT$227.6 million | -11.7% | -53.2% |
| Dec 2024 | NT$486 million | +32.1% | +63.6% |
| Nov 2024 | NT$297.1 million | -22.1% | +25.1% |
| Oct 2024 | NT$237.5 million | -66.2% | -50.9% |
Jan–Oct 2026 cumulative: NT$3.84 billion (+9.0% YoY)
Other Biotech & Medical companies
Compare with peers: CHC vs PEC / CHC vs Lotus Pharm / CHC vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16